← Back to all signals
RESEARCH PAPER ANALYSIS

Beyond motor control: The subthalamic nucleus as a central hub for pain in Parkinson's disease.

This review consolidates anatomical, physiological, preclinical and clinical evidence that the subthalamic nucleus integrates nociceptive signals in Parkinson’s disease, that pathological STN firing and beta oscillations exacerbate pain, and that STN-DBS and targeted circuit modulation reduce…

PMID42002247
JournalNeuroscience and biobehavioral reviews
Publication Date2026-04-17
Ingested2026-04-28 08:58 PM
EXECUTIVE SUMMARY

What the AI sees

This review consolidates anatomical, physiological, preclinical and clinical evidence that the subthalamic nucleus integrates nociceptive signals in Parkinson’s disease, that pathological STN firing and beta oscillations exacerbate pain, and that STN-DBS and targeted circuit modulation reduce…

WHY IT MATTERS

Research significance

By positioning the STN as a mechanistic hub for PD pain and linking symptom relief to suppression of pathological firing patterns, the paper highlights actionable therapeutic routes—neuromodulation parameters, oscillatory biomarkers, and circuit-specific interventions—that can be translated into…

ABSTRACT

Source abstract

The subthalamic nucleus (STN), considered a primarily motor structure within the basal ganglia, is recognized as a key contributor to a wider set of behaviors. Among these, nociceptive processing has gained particular attention, especially given the high prevalence and early emergence of pain in Parkinson's disease (PD). This review brings together anatomical, physiological and translational evidence to examine how the STN integrates motor and nociceptive information. The STN receives ascending afferents from brainstem nociceptive pathways and its activity tracks the intensity and salience of noxious stimuli, recruiting cortical and limbic networks that shape both sensory and affective dimensions of pain. In PD, the organization and dynamics of the STN are profoundly disrupted. Abnormal bursting and exaggerated beta oscillations, central to motor symptoms, also appear to promote central sensitization and enhanced pain responses. Studies from animal models consistently support the notion that parkinsonian states perturbate nociceptive signaling within the STN. Deep brain stimulation (DBS) of the STN, a well-established therapy for motor symptoms, further demonstrates the involvement of the nucleus in the pathophysiology of pain. Evidence from clinical and preclinical studies indicates that STN-DBS attenuates nociceptive hypersensitivity and modulates pain processing at spinal level, suggesting an intrinsic analgesic action rather than a secondary effect of motor improvement. Finally, recent optogenetic and chemogenetic approaches clarified how therapeutic interventions act on STN circuits, showing that symptom relief is linked to the suppression of pathological firing patterns. Together, these findings position the STN as a central node linking motor and pain networks in PD.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 The cGAS-STING-Glymphatic-gut Axis in Parkinson's disease: A proposed self-amplifying triad of Neuroinflammation and therapeutic opportunity. International immunopharmacology 91.0 2 Immunosenescence and Inflammaging as Drivers of Neurodegeneration: Cellular Mechanisms, Neuroimmune Crosstalk, and Therapeutic Implications. Cells 91.0 3 Flavonoids improve neurotransmitters for Parkinson's treatment: mechanism and therapeutic potential. Frontiers in pharmacology 88.0 4 Alpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives. Neurology international 78.0 5 The Gut Microbiota in Parkinson's Disease: Mechanistic Insights into Microbial-Host Interactions. Microorganisms 85.0 6 Linking inflammation, metabolic dysfunction, and neurodegeneration: a comprehensive review of TLR2 pathways in type 2 diabetes. Frontiers in clinical diabetes and healthcare 80.0 7 Neuroprotective effects of GLP-2 and a GLP-2/GIP dual receptor agonist in an MPTP-induced mouse model of Parkinson's disease. Peptides 86.0 8 TNF alpha unmasks enteric malate aspartate shuttle dysfunction bridging Parkinson disease and intestinal inflammation. Nature communications 91.5 9 Lipid Metabolism and Neurodegeneration: Mechanistic Insights and Therapeutic Targets. Ageing research reviews 82.0 10 Shared functional microbiome signatures in Parkinson's disease and constipation predominate irritable bowel syndrome despite taxonomic divergence. Brain, behavior, & immunity - health 80.0 11 Benzimidazole as a Versatile Scaffold for Developing Neurotherapeutics Against Neurodegenerative Diseases. ChemMedChem 74.0 12 Biomimicking neuromelanin reverses the gait deficits and dopaminergic neuronal loss in the Parkinson's disease. Colloids and surfaces. B, Biointerfaces 86.0 13 Neuroprotective roles of klotho: Molecular pathways and therapeutic implications for cognitive health in neurological and psychiatric diseases. Experimental physiology 84.0 14 Flavonoid Rutin Reduces Intestinal Inflammation in an Experimental Model of Parkinson's Disease. Neurotoxicity research 70.0 15 Nanostructured Lipid Carriers Enhance Brain Delivery and Antioxidant Efficacy of a Small-Molecule MAO B Inhibitor for Neurodegenerative Disease Therapy. Molecular pharmaceutics 78.0 16 Pathophysiological Role of the Gut Brain Axis in Parkinson's Disease: From Microbial Metabolites and Intestinal Permeability to Central Neuroinflammation. Current neurovascular research 86.0 17 Parkinson's Disease: From Metabolism to Genetics-A Comprehensive Review. Current issues in molecular biology 86.0 18 Navigating the cholesterol maze: Key insights on use of statins in neurodegenerative disorders. Neuroprotection (Chichester, England) 76.0 19 Integrative network pharmacology delineates dual GPCR and non-GPCR mechanisms of blended and individual Taikong Blue lavender and Pingyin rose essential oils in neurodegenerative and psychiatric disorders. Computers in biology and medicine 65.0 20 Models of neuroprotection in Parkinson's disease: Exploring cellular, molecular, and microenvironmental targets. Experimental neurology 78.0 21 Hyaluronic acid: emerging roles and biomaterial innovations in Alzheimer's and Parkinson's disease therapy. Frontiers in pharmacology 75.2 22 Molecular mechanisms underlying Parkinson's disease and role of phytochemicals, α-synuclein, sirtuins, and incretin mimetics in potential therapy. Frontiers in pharmacology 75.0 23 Lipid droplets in neurodegenerative diseases: pathological drivers and therapeutic vulnerabilities. Cell death discovery 82.0 24 Brain-gut-microbiota axis: a review on the bidirectional regulatory mechanisms between gut microbiota and brain and their disease interactions. Frontiers in microbiology 74.0 25 Long non-coding RNAs in neurodegenerative diseases - Molecular mechanisms, liquid biopsy biomarkers, and therapeutic targets: A review. Biomolecules & biomedicine 84.0 26 Neurosyphilis and Parkinsonism: Overlapping Pathophysiology and Emerging Therapeutic Insights. Current neurovascular research 76.0 27 Molecular biochemistry of soluble epoxide hydrolase in lipid mediator pathways and neuroinflammatory responses. The Journal of steroid biochemistry and molecular biology 82.0 28 Multifaceted role of CNPY2 beyond ER stress: Disease implications and therapeutic potential. Cell stress 83.3 29 Neuroprotective Role of Exercise-based Physiotherapy Combined with Pharmacological Agents in Parkinson's Disease. Central nervous system agents in medicinal chemistry 64.0 30 Distinct metabolomic and proteomic signatures in Parkinson's disease patients with REM sleep behavior disorder. Signal transduction and targeted therapy 84.0 31 HMGB1-mediated neuroinflammation: molecular mechanisms and emerging therapeutic approaches. Inflammopharmacology 78.0 32 Beyond acid-base dyshomeostasis: Dynamic instability of neuronal lysosomal pH as a pathogenic mechanism and therapeutic target in neurological diseases. Biochemical pharmacology 88.0
Neurocompute Parkinson’s Narrative Velocity Infographic
NEUROCOMPUTE VISUAL SYSTEM

Open the Narrative Velocity Map

Explore the full Parkinson’s research intelligence diagram.

Expand Intelligence View →
Full Neurocompute Infographic